Impact of baseline steroids on the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma

Figure 5 Long-term efficacy assessment. A: Comparison of overall survival (OS) between the dexamethasone and antihistamine groups. The log-rank test P value is 0.51, indicating no statistically significant difference in OS between the two groups; B: Comparison of progression-free survival (PFS) between the dexamethasone and antihistamine groups. The log-rank test P value is 0.49, indicating no statistically significant difference in PFS between the two groups; C: Comparison of OS between the < 20 mg dexamethasone group and the 20 mg dexamethasone group. The log-rank test P value is 0.13, indicating no statistically significant difference in OS between the two groups; D: Comparison of PFS between the < 20 mg dexamethasone group and the 20 mg dexamethasone group. The log-rank test P value is 0.0014, indicating a statistically significant difference in PFS between the two dosage groups, suggesting that 20 mg of dexamethasone may lead to better PFS outcomes. OS: Overall survival; PFS: Progression-free survival.